Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Dexamethasone

First Posted Date: 2005-11-01

Last Posted Date: 2014-03-07

Lead Sponsor: Susanne Arnold

Target Recruit Count: 60

Registration Number: NCT00247416

Locations: 🇺🇸
Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
St. Claire Regional Medical Center, Morehead, Kentucky, United States
🇺🇸
Commonwealth Cancer Center, Danville, Kentucky, United States

and more 4 locations

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel
Other: placebo

First Posted Date: 2005-10-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 296

Registration Number: NCT00245154

Locations: 🇨🇦
University Institute of Cardiology and, Quebec, Canada
🇷🇴
Oncological Institute "Ion Chiricuta", Cluj-Napoca, Romania
🇷🇴
Clinical County Hospital of Sibiu, Sibiu, Romania

and more 17 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2005-10-13

Last Posted Date: 2013-05-17

Lead Sponsor: University of Washington

Target Recruit Count: 18

Registration Number: NCT00238147

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Phase 1

Terminated

Conditions: Bone Marrow Suppression
Brain and Central Nervous System Tumors
Drug/Agent Toxicity by Tissue/Organ
Long-term Effects Secondary to Cancer Therapy in Children

First Posted Date: 2005-10-13

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00238173

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Cancer

Interventions: Drug: Docetaxel
Drug: Carboplatin
Procedure: Radiation therapy
Procedure: Surgical resection

First Posted Date: 2005-10-13

Last Posted Date: 2015-05-12

Lead Sponsor: Stanford University

Target Recruit Count: 13

Registration Number: NCT00238615

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2005-10-06

Last Posted Date: 2019-06-04

Lead Sponsor: Northwestern University

Target Recruit Count: 51

Registration Number: NCT00234052

Locations: 🇺🇸
Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States

and more 2 locations

Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2005-10-04

Last Posted Date: 2005-11-03

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 75

Registration Number: NCT00231075

Locations: 🇫🇷
Centre Hospitalier Lyon-sud, Pierre-Bénite, France
🇫🇷
Centre Hosptalier Emile Roux, Eaubonne, France

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: cetuximab
Drug: carboplatin

First Posted Date: 2005-10-04

Last Posted Date: 2017-06-28

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 112

Registration Number: NCT00232505

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 11 locations

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Phase 2

Completed

Conditions: Testicular Neoplasms

Interventions: Drug: epirubicin
Procedure: high-dose and autologous stem cell transplantation
Drug: paclitaxel
Drug: etoposide
Drug: ifosfamide
Drug: carboplatin

First Posted Date: 2005-10-04

Last Posted Date: 2011-02-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 50

Registration Number: NCT00231582

Locations: 🇫🇷
Hôpital TENON, Service d'Oncologie Médicale, Paris, France

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2005-10-03

Last Posted Date: 2018-08-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 44

Registration Number: NCT00230542

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy